Skin toxicity related to targeted therapy

Internationally accredited e-learning on skin toxicity related to targeted therapy in liver and GI cancer

An interactive e-learning to help physicians and nurses improve their understanding of skin reactions related to targeted therapy in liver and GI cancers, so that they may prevent, diagnose and manage these dermatologic adverse events and involve a multidisciplinary team to provide the best possible patient care.

Find out more about the programme in this short video:

An expert faculty have developed this e-learning

  • Dr Catherine Frenette, hepatologist from San Diego, USA (HCC CONNECT)
  • Dr Victor Hugo Fonseca de Jesus, medical oncologist from São Paulo, Brazil (GI CONNECT)
  • Natasha Pinheiro, nurse practitioner from New York, USA (GI Nurses CONNECT)
  • Dr Nicole LeBoeuf, dermatologist from Boston, USA
  •  

Start your learning journey now:

  • Launch your interactive e-learning https://checkpoint.cor2ed.com
  • Download the slide deck summarising the educational content of this course
  • Obtain your own copy of our helpful leaflet to give to your patients
A number of recognised CME credits are available after completing this e-learning course. The e-learning is accredited for European CME Credits (ECMECs) and certified for AMA PRA Category 1 CreditsTM as well as American Board of Internal Medicine (ABIM) MOC credit.

Targeted therapies lead to more dermatologic adverse events than are seen with non-targeted therapies. Skin toxicity may lead to changes in dosing, physical and psychological discomfort or pain, therefore increasing the risk of total treatment interruption, potentially leading to exacerbation of the patient’s cancer. Pre-emptively addressing and treating these potential skin toxicities may improve the quality of life for the patient and allow them to continue on therapy longer. A multidisciplinary team effort amongst healthcare professionals in the prevention, diagnosis, and management of skin toxicities associated with targeted therapy in liver and GI cancers, including hepatocellular carcinoma, colorectal cancer, pancreatic cancer, neuroendocrine tumours, gastric cancer and GIST is widely recommended as a best practice approach.

This e-learning course aims to support your understanding of adverse skin reactions to targeted therapy in liver and GI cancers, helping you to prevent and manage skin toxicities related to targeted therapies in liver and GI cancers and enabling you to involve a multidisciplinary team in the prevention, diagnosis, and management of skin toxicities associated with targeted therapy in liver and GI cancers.

This course has been created as a collaboration between HCC CONNECT, GI Nurses CONNECT and GI CONNECT, supported by an independent educational grant from Bayer.